$RARE

Ultragenyx Pharmaceutical Inc. recently presented at the Barclays 28th Annual Global Healthcare Conference, highlighting advancements in their pipeline and strategic initiatives moving forward. The focus on expanding research into rare diseases could lead to potential growth and increased investor interest. The management emphasized upcoming milestones, including potential FDA submissions and clinical trial updates. The overall tone of the presentation was positive, boosting confidence in the company's future. Market responses from analysts following the presentation indicate a generally optimistic outlook for the stock.

Corn futures are experiencing losses of 4 to 6 cents as they trade lower, impacted by a notable drop in crude oil prices. Recent USDA reports have not provided any surprises to the market, which may have contributed to the subdued trading activity. Cash corn prices have also fallen, with a national average at $4.05 ½, reflecting a significant decline. The increased risk premium in the crude oil market is suggesting further volatility ahead. Overall, these factors indicate increased bearish sentiment for corn and related commodities.